Compare Glenmark Pharma with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 14.0 28.8 48.7% View Chart
P/BV x 2.0 4.0 50.8% View Chart
Dividend Yield % 0.5 0.6 89.3%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
CIPLA
Mar-21
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs573879 65.2%   
Low Rs195411 47.6%   
Sales per share (Unadj.) Rs387.8237.6 163.3%  
Earnings per share (Unadj.) Rs34.429.8 115.5%  
Cash flow per share (Unadj.) Rs50.142.2 118.7%  
Dividends per share (Unadj.) Rs2.505.00 50.0%  
Avg Dividend yield %0.70.8 83.9%  
Book value per share (Unadj.) Rs249.6226.7 110.1%  
Shares outstanding (eoy) m282.17806.46 35.0%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.02.7 36.5%   
Avg P/E ratio x11.221.6 51.6%  
P/CF ratio (eoy) x7.715.3 50.2%  
Price / Book Value ratio x1.52.8 54.1%  
Dividend payout %7.316.8 43.3%   
Avg Mkt Cap Rs m108,353519,826 20.8%   
No. of employees `000NANA-   
Total wages/salary Rs m23,43732,518 72.1%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m109,439191,596 57.1%  
Other income Rs m5022,698 18.6%   
Total revenues Rs m109,941194,294 56.6%   
Gross profit Rs m21,28941,841 50.9%  
Depreciation Rs m4,43610,031 44.2%   
Interest Rs m3,5311,607 219.7%   
Profit before tax Rs m13,82532,901 42.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,1248,888 46.4%   
Profit after tax Rs m9,70124,013 40.4%  
Gross profit margin %19.521.8 89.1%  
Effective tax rate %29.827.0 110.4%   
Net profit margin %8.912.5 70.7%  
BALANCE SHEET DATA
Current assets Rs m73,596132,095 55.7%   
Current liabilities Rs m42,01045,916 91.5%   
Net working cap to sales %28.945.0 64.2%  
Current ratio x1.82.9 60.9%  
Inventory Days Days768 9.8%  
Debtors Days Days867 1,306.8%  
Net fixed assets Rs m67,093116,277 57.7%   
Share capital Rs m2821,613 17.5%   
"Free" reserves Rs m70,148181,232 38.7%   
Net worth Rs m70,430182,844 38.5%   
Long term debt Rs m38,88812,028 323.3%   
Total assets Rs m140,689248,372 56.6%  
Interest coverage x4.921.5 22.9%   
Debt to equity ratio x0.60.1 839.4%  
Sales to assets ratio x0.80.8 100.8%   
Return on assets %9.410.3 91.2%  
Return on equity %13.813.1 104.9%  
Return on capital %15.917.7 89.7%  
Exports to sales %031.3 0.0%   
Imports to sales %010.9 0.0%   
Exports (fob) Rs mNA59,951 0.0%   
Imports (cif) Rs mNA20,911 0.0%   
Fx inflow Rs m35,75368,051 52.5%   
Fx outflow Rs m12,02320,911 57.5%   
Net fx Rs m23,72947,140 50.3%   
CASH FLOW
From Operations Rs m11,31237,552 30.1%  
From Investments Rs m-6,752-23,872 28.3%  
From Financial Activity Rs m-4,418-13,299 33.2%  
Net Cashflow Rs m278509 54.6%  

Share Holding

Indian Promoters % 46.7 14.3 325.8%  
Foreign collaborators % 0.0 21.8 -  
Indian inst/Mut Fund % 35.0 45.8 76.3%  
FIIs % 25.9 24.8 104.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 63.9 83.5%  
Shareholders   329,870 410,831 80.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   BROOKS LAB  AUROBINDO PHARMA  PROCTER & GAMBLE HEALTH  PHAARMASIA  KOPRAN.  



Today's Market

Sensex Ends 383 Points Higher; Metal and Realty Stocks Rally(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

CIPLA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of CIPLA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

More Views on News

Most Popular

5 Green Energy Stocks to Watch as India Readies for a Revolution(Views On News)

Oct 13, 2021

The excitement around green energy stocks has opened up a huge contrarian opportunity in the traditional energy space.

Could HDFC Bank be a Big EV Winner? The Answer Will Surprise You...(Profit Hunter)

Oct 13, 2021

Why should investors take it for granted that India's Tesla will be one of the major auto stocks?

Tata Group Stocks are on Fire: Which one Should You Buy?(Profit Hunter)

Oct 15, 2021

Tata group stocks are on fire. Find out which one deserves your attention.

Massive Surge in the Shares of Tata Motors Today. Key Factors Favouring the Rally(Views On News)

Oct 13, 2021

Tata Motors zooms 23% after report of TPG investing Rs 75 bn in EV arm.

India's Big PSU Selloff: Watch Out for these Top Stocks(Views On News)

Oct 15, 2021

The government's plan to divest its stakes in PSUs could spark off a rally in these four stocks.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 26, 2021 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS